Journal articleJ Immunother2010

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

DOI 10.1097/cji.0b013e3181eec14c ↗ Europe PMC, retrieved 5 November 2026

Journal: J Immunother
Published: 1 October 2010
Citations: 1,012

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 4

Its registry lists this paper as resultsMDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery NCT00112580 ↗
BackgroundNALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NCT07595172 ↗
BackgroundExploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With … NCT04787991 ↗
BackgroundSBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer NCT02704156 ↗

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.